A multi-site feasibility study for personalized medicine in canines with Osteosarcoma

Journal of Translational Medicine

Volumn 11, Issue 1, 2013, Pages

  Monks, Noel R ^a   Cherba, David M ^a   Kamerling, Steven G ^b   Simpson, Heather ^b   Rusk, Anthony W ^c   Carter, Derrick ^c   Eugster, Emily ^a   Mooney, Marie ^a   Sigler, Robert ^d   Steensma, Matthew ^a   Grabinski, Tessa ^a   Marotti, Keith R ^b   Webb, Craig P ^a  

^a VAN ANDEL RESEARCH INSTITUTE   (United States)

^b ZOETIS   (United States)

^c Animal Clinical Investigation LLC   (United States)

^d Research Essential Services LLC   (United States)

Author keywords

Canine; Drug prediction; Feasibility trial; Gene expression; Osteosarcoma; Personalized medicine

Indexed keywords

VETERINARY DRUG; PARAFFIN;

ANIMAL TISSUE; ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DOG DISEASE; FEASIBILITY STUDY; FEMALE; FROZEN SECTION; GENE EXPRESSION; GENE MAPPING; GENE PROBE; GENETIC ALGORITHM; GENOMICS; HISTOPATHOLOGY; LABORATORY TEST; LIMB AMPUTATION; MALE; MEDICAL EDUCATION; NONHUMAN; OSTEOSARCOMA; PERSONALIZED MEDICINE; PREDICTION; PROSPECTIVE STUDY; RNA EXTRACTION; SCORING SYSTEM; TISSUE SECTION; VETERINARY MEDICINE; ANIMAL; DOG; DOG DISEASES; MULTICENTER STUDY; PRINCIPAL COMPONENT ANALYSIS; QUALITY CONTROL; TIME; TISSUE FIXATION; VETERINARY;

ANIMALS; DOG DISEASES; DOGS; FEASIBILITY STUDIES; FEMALE; INDIVIDUALIZED MEDICINE; MALE; OSTEOSARCOMA; PARAFFIN EMBEDDING; PRINCIPAL COMPONENT ANALYSIS; QUALITY CONTROL; TIME FACTORS; TISSUE FIXATION;

EID: 84879471843     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-11-158     Document Type: Article

References (48)

1. Awada A, Vandone AM, Aftimos P. Personalized management of patients with solid cancers: moving from patient characteristics to tumor biology. Curr Opin Oncol 2012, 24:297-304. 10.1097/CCO.0b013e3283521349, 22410457.
2. Gasparini G, Longo R. The paradigm of personalized therapy in oncology. Expert Opin Ther Targets 2012, 16(Suppl 1):S7-S16.
3. Yap TA, Workman P. Exploiting the cancer genome: strategies for the discovery and clinical development of targeted molecular therapeutics. Annu Rev Pharmacol Toxicol 2012, 52:549-573. 10.1146/annurev-pharmtox-010611-134532, 22235862.
4. Blay JY, Le Cesne A, Cassier PA, Ray-Coquard IL. Gastrointestinal Stromal Tumors (GIST): a rare entity, a tumor model for personalized therapy, and yet ten different molecular subtypes. Discov Med 2012, 13:357-367.
5. Yap TA, Gerlinger M, Futreal PA, Pusztai L, Swanton C. Intratumor heterogeneity: seeing the wood for the trees. Sci Transl Med 2012, 4:127. ps110.
6. Diamandis M, White NM, Yousef GM. Personalized medicine: marking a new epoch in cancer patient management. Mol Cancer Res 2010, 8:1175-1187. 10.1158/1541-7786.MCR-10-0264, 20693306.
7. Druker BJ, Lydon NB. Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia. J Clin Invest 2000, 105:3-7. 10.1172/JCI9083, 382593, 10619854.
8. Bollag G, Hirth P, Tsai J, Zhang J, Ibrahim PN, Cho H, Spevak W, Zhang C, Zhang Y, Habets G, et al. Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature 2010, 467:596-599. 10.1038/nature09454, 2948082, 20823850.
9. Conlin AK, Seidman AD. Use of the Oncotype DX 21-gene assay to guide adjuvant decision making in early-stage breast cancer. Mol Diagn Ther 2007, 11:355-360. 10.1007/BF03256259, 18078353.
10. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004, 351:2817-2826. 10.1056/NEJMoa041588, 15591335.
11. Webber EM, Lin JS, Whitlock EP. Oncotype DX tumor gene expression profiling in stage II colon cancer. Application: prognostic, risk prediction. PLoS Curr 2010, 2:1.
12. Van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, Mao M, Peterse HL, van der Kooy K, Marton MJ, Witteveen AT, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002, 415:530-536. 10.1038/415530a, 11823860.
13. O'Donnell PH, Ratain MJ. Germline pharmacogenomics in oncology: decoding the patient for targeting therapy. Mol Oncol 2012, 6:251-259. 10.1016/j.molonc.2012.01.005, 22321460.
14. Ellis LM, Fidler IJ. Finding the tumor copycat. Therapy fails, patients don't. Nat Med 2010, 16:974-975. 10.1038/nm0910-974, 20823880.
15. Monsma DJ, Monks NR, Cherba DM, Dylewski D, Eugster E, Jahn H, Srikanth S, Scott SB, Richardson PJ, Everts RE, et al. Genomic characterization of explant tumorgraft models derived from fresh patient tumor tissue. J Transl Med 2012, 10:125. 10.1186/1479-5876-10-125, 3439334, 22709571.
16. Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nat Rev Clin Oncol 2012, 9:338-350. 10.1038/nrclinonc.2012.61, 22508028.
17. Paoloni M, Khanna C. Translation of new cancer treatments from pet dogs to humans. Nat Rev Cancer 2008, 8:147-156. 10.1038/nrc2273, 18202698.
18. Rowell JL, McCarthy DO, Alvarez CE. Dog models of naturally occurring cancer. Trends Mol Med 2011, 17:380-388. 10.1016/j.molmed.2011.02.004, 3130881, 21439907.
19. Sargan DR. IDID: inherited diseases in dogs: web-based information for canine inherited disease genetics. Mamm Genome 2004, 15:503-506. 10.1007/s00335-004-3047-z, 15181542.
20. Lindblad-Toh K, Wade CM, Mikkelsen TS, Karlsson EK, Jaffe DB, Kamal M, Clamp M, Chang JL, Kulbokas EJ, Zody MC, et al. Genome sequence, comparative analysis and haplotype structure of the domestic dog. Nature 2005, 438:803-819. 10.1038/nature04338, 16341006.
21. Ostrander EA, Galibert F, Patterson DF. Canine genetics comes of age. Trends Genet 2000, 16:117-124. 10.1016/S0168-9525(99)01958-7, 10689352.
22. Rankin KS, Starkey M, Lunec J, Gerrand CH, Murphy S, Biswas S. Of dogs and men: comparative biology as a tool for the discovery of novel biomarkers and drug development targets in osteosarcoma. Pediatr Blood Cancer 2012, 58:327-333. 10.1002/pbc.23341, 21990244.
23. Parker HG, Shearin AL, Ostrander EA. Man's best friend becomes biology's best in show: genome analyses in the domestic dog. Annu Rev Genet 2010, 44:309-336. 10.1146/annurev-genet-102808-115200, 3322674, 21047261.
24. Morello E, Martano M, Buracco P. Biology, diagnosis and treatment of canine appendicular osteosarcoma: similarities and differences with human osteosarcoma. Vet J 2011, 189:268-277. 10.1016/j.tvjl.2010.08.014, 20889358.
25. Withrow SJ, Wilkins RM. Cross talk from pets to people: translational osteosarcoma treatments. ILAR J 2010, 51:208-213. 10.1093/ilar.51.3.208, 21131721.
26. Dernell WS, Ehrhart NP, Straw RC, Vail DM. Tumors of the Skeletal System. Withrow and MacEwen's Small Animal Clinical Oncology 2007, 540-582. St. Louis: Elsevier, Withrow SJ, Vail DM.
27. Rosenberger JA, Pablo NV, Crawford PC. Prevalence of and intrinsic risk factors for appendicular osteosarcoma in dogs: 179 cases (1996-2005). J Am Vet Med Assoc 2007, 231:1076-1080. 10.2460/javma.231.7.1076, 17916033.
28. Ru G, Terracini B, Glickman LT. Host related risk factors for canine osteosarcoma. Vet J 1998, 156:31-39. 10.1016/S1090-0233(98)80059-2, 9691849.
29. Selvarajah GT, Kirpensteijn J, van Wolferen ME, Rao NA, Fieten H, Mol JA. Gene expression profiling of canine osteosarcoma reveals genes associated with short and long survival times. Mol Cancer 2009, 8:72. 10.1186/1476-4598-8-72, 2746177, 19735553.
30. O'Donoghue LE, Ptitsyn AA, Kamstock DA, Siebert J, Thomas RS, Duval DL. Expression profiling in canine osteosarcoma: identification of biomarkers and pathways associated with outcome. BMC Cancer 2010, 10:506. 10.1186/1471-2407-10-506, 2955038, 20860831.
31. Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, et al. DrugBank 3.0: a comprehensive resource for 'omics' research on drugs. Nucleic Acids Res 2011, 39:D1035-D1041. 10.1093/nar/gkq1126, 3013709, 21059682.
32. Von Hoff DD, Stephenson JJ, Rosen P, Loesch DM, Borad MJ, Anthony S, Jameson G, Brown S, Cantafio N, Richards DA, et al. Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers. J Clin Oncol 2010, 28:4877-4883. 10.1200/JCO.2009.26.5983, 20921468.
33. Furge KA, Chen J, Koeman J, Swiatek P, Dykema K, Lucin K, Kahnoski R, Yang XJ, Teh BT. Detection of DNA copy number changes and oncogenic signaling abnormalities from gene expression data reveals MYC activation in high-grade papillary renal cell carcinoma. Cancer Res 2007, 67:3171-3176. 10.1158/0008-5472.CAN-06-4571, 17409424.
34. Lamb J, Crawford ED, Peck D, Modell JW, Blat IC, Wrobel MJ, Lerner J, Brunet JP, Subramanian A, Ross KN, et al. The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease. Science 2006, 313:1929-1935. 10.1126/science.1132939, 17008526.
35. Dezso Z, Nikolsky Y, Nikolskaya T, Miller J, Cherba D, Webb C, Bugrim A. Identifying disease-specific genes based on their topological significance in protein networks. BMC Syst Biol 2009, 3:36. 10.1186/1752-0509-3-36, 2678983, 19309513.
36. Torkamani A, Schork NJ. Background gene expression networks significantly enhance drug response prediction by transcriptional profiling. Pharmacogenomics J 2012, 12:446-452. 10.1038/tpj.2011.35, 21826086.
37. Schroeder A, Mueller O, Stocker S, Salowsky R, Leiber M, Gassmann M, Lightfoot S, Menzel W, Granzow M, Ragg T. The RIN: an RNA integrity number for assigning integrity values to RNA measurements. BMC Mol Biol 2006, 7:3. 10.1186/1471-2199-7-3, 1413964, 16448564.
38. Saulnier Sholler GL, Ferguson W, Bergendahl G, Currier E, Lenox SR, Bond J, Slavik M, Roberts W, Mitchell D, Eslin D, et al. A pilot trial testing the feasibility of using molecular-guided therapy in patients with recurrent neuroblastoma. Journal of Cancer Therapy 2012, 3:602-612.
39. Mazzarella R, Webb CP. Computational and bioinformatic strategies in indications discovery research. Drug Repositioning: Bringing new life to shelved assets and existing drugs 2012, 91-128. New York: John Wiley & Sons, Inc, Barratt MJ, Frail DE.
40. Gheeya JS, Chen QR, Benjamin CD, Cheuk AT, Tsang P, Chung JY, Metaferia BB, Badgett TC, Johansson P, Wei JS, et al. Screening a panel of drugs with diverse mechanisms of action yields potential therapeutic agents against neuroblastoma. Cancer Biol Ther 2009, 8:2386-2395. 10.4161/cbt.8.24.10184, 2829338, 19946221.
41. Lee JK, Havaleshko DM, Cho H, Weinstein JN, Kaldjian EP, Karpovich J, Grimshaw A, Theodorescu D. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc Natl Acad Sci USA 2007, 104:13086-13091. 10.1073/pnas.0610292104, 1941805, 17666531.
42. Staunton JE, Slonim DK, Coller HA, Tamayo P, Angelo MJ, Park J, Scherf U, Lee JK, Reinhold WO, Weinstein JN, et al. Chemosensitivity prediction by transcriptional profiling. Proc Natl Acad Sci USA 2001, 98:10787-10792. 10.1073/pnas.191368598, 58553, 11553813.
43. Lane A, Black M, Wyatt K. Toxicity and efficacy of a novel doxorubicin and carboplatin chemotherapy protocol for the treatment of canine appendicular osteosarcoma following limb amputation. Aust Vet J 2012, 90:69-74. 10.1111/j.1751-0813.2011.00878.x, 22339117.
44. London CA. Tyrosine kinase inhibitors in veterinary medicine. Top Companion Anim Med 2009, 24:106-112. 10.1053/j.tcam.2009.02.002, 19732728.
45. Berg J, Gebhardt MC, Rand WM. Effect of timing of postoperative chemotherapy on survival of dogs with osteosarcoma. Cancer 1997, 79:1343-1350. 10.1002/(SICI)1097-0142(19970401)79:7<1343::AID-CNCR11>3.0.CO;2-#, 9083156.
46. Cronin M, Ross JS. Comprehensive next-generation cancer genome sequencing in the era of targeted therapy and personalized oncology. Biomark Med 2011, 5:293-305. 10.2217/bmm.11.37, 21657839.
47. Russnes HG, Navin N, Hicks J, Borresen-Dale AL. Insight into the heterogeneity of breast cancer through next-generation sequencing. J Clin Invest 2011, 121:3810-3818. 10.1172/JCI57088, 3195464, 21965338.
48. Stricker T, Catenacci DV, Seiwert TY. Molecular profiling of cancer-the future of personalized cancer medicine: a primer on cancer biology and the tools necessary to bring molecular testing to the clinic. Semin Oncol 2011, 38:173-185. 10.1053/j.seminoncol.2011.01.013, 21421108.